These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 32243027)

  • 1. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
    Brennan Y; Parikh S; McRae S; Tran H
    Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
    Tortella BJ; Alvir J; McDonald M; Spurden D; Fogarty PF; Chhabra A; Pleil AM
    J Manag Care Spec Pharm; 2018 Jul; 24(7):643-653. PubMed ID: 29363389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
    Carcao M; Zunino L; Young NL; Dover S; Bouskill V; Hilliard P; Price VE; Blanchette VS
    Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of treatment and outcome for patients with haemophilia A and haemophilia B on extended half-life (EHL) factor products: A 12-month data analysis.
    George C; Parikh S; Carter T; Mccosker J; Carlino S; Tran H
    Haemophilia; 2023 Sep; 29(5):1283-1290. PubMed ID: 37565529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B.
    Rampotas A; Desborough MJR; Raza-Burton S; Taylor S; Wilkinson A; Hall GW; Shapiro S; Curry N
    Haemophilia; 2020 Mar; 26(2):278-281. PubMed ID: 32083769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
    Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
    Wang C; Young G
    Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical application of extended half-life factor VIII in children with severe haemophilia A.
    Dettoraki A; Michalopoulou A; Mazarakis M; Saslis S; Stamati I; Kapsimali Z; Pergantou H
    Haemophilia; 2022 Jul; 28(4):619-624. PubMed ID: 35503081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
    Lehtinen AE; Baghaei F; Astermark J; Holme PA
    Haemophilia; 2022 Sep; 28(5):713-719. PubMed ID: 35575446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes.
    Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
    Haemophilia; 2021 Sep; 27(5):751-759. PubMed ID: 34160870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
    Aledort L; Milligan S; Watt M; Booth J
    J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
    von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
    Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
    Shapiro A; Chaudhury A; Wang M; Escobar M; Tsao E; Barnowski C; Feng J; Jain N; Quon DV
    Haemophilia; 2020 Nov; 26(6):975-983. PubMed ID: 33012060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B.
    Chhabra A; Spurden D; Fogarty PF; Tortella BJ; Rubinstein E; Harris S; Pleil AM; Mellor J; de Courcy J; Alvir J
    Blood Coagul Fibrinolysis; 2020 Apr; 31(3):186-192. PubMed ID: 32271314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria.
    Ay C; Feistritzer C; Rettl J; Schuster G; Vavrovsky A; Perschy L; Pabinger I
    Sci Rep; 2021 Jun; 11(1):12967. PubMed ID: 34155229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world experience with use of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A.
    Dunn AL; Ahuja SP; Mullins ES
    Haemophilia; 2018 May; 24(3):e84-e92. PubMed ID: 29359417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.